Malignant Disease
Malignant Disease
Overview
Malignant disease refers to a class of disorders characterized by the uncontrolled growth, invasion, and spread of abnormal cells, most commonly used in biomedical contexts to denote cancer and malignant tumors. Biologically, malignant disease is defined by the capacity of transformed cells to evade normal growth control, resist cell death, remodel surrounding tissue, and metastasize to distant sites. These properties make malignant disease a major cause of morbidity and mortality worldwide and a central focus of oncology, immunology, molecular biology, and translational medicine.
In recent research, malignant disease has been studied not only as a clinical endpoint but also as a therapeutic target for precision oncology, immunotherapy, gene editing, and nanomedicine. Investigations frequently intersect with tumor microenvironment biology, checkpoint inhibitor, T-lymphocytes, natural killer (NK) cells, dendritic cell targeting, STING1 signaling, toll-like receptor pathways, and mitochondrial dysfunction. The term also appears in broader disease frameworks linking cancer with oxidative stress, chronic inflammation, metabolic dysfunction–associated steatotic liver disease, cardiovascular disease, and other age-related disorders.
Focus of Latest Publications
Recent publications show malignant disease being addressed across a wide range of therapeutic and diagnostic strategies, with cancer and malignant tumors serving as the principal biological context.
Several studies focused on immunotherapy. A review of bispecific T cell engagers and higher-order multispecific immunotherapeutics described engineered antibodies that redirect immune effector cells toward tumor targets, thereby eliciting coordinated antitumor immune responses. Other work examined immune checkpoint inhibitors, noting that these agents have transformed cancer treatment by enhancing antitumor immunity, although durable responses occur in only a fraction of patients. Related publications discussed vaccine safety in individuals receiving immune checkpoint inhibitor therapy and the use of pneumococcal conjugate vaccines in children with cancer or other immunocompromising conditions, reflecting the clinical overlap between malignant disease and immune modulation. Additional studies explored dendritic cell targeting, dendritic cell extracellular vesicles, and lipid-based delivery systems for dendritic cell targeting as platforms for more effective and durable cancer immunotherapies.
Cell-based and receptor-engineered therapies were also prominent. Research on chimeric antigen receptor (CAR) approaches included edited CAR-T cells with enhanced cytotoxicity and complete tumor clearance in vivo, as well as work on affinity tuning to balance efficacy and safety by reducing cytokine release syndrome. A separate study on TIGIT base editing in natural killer cells showed that TIGIT BE-NK cells specifically targeted cancer cells across multiple tumor types and were validated as safe with minimal off-target effects. These findings align with broader efforts to improve immune cell specificity against malignant disease while limiting toxicity.
Multiple publications addressed molecular and pathway-level mechanisms relevant to malignant disease. Reviews and computational studies highlighted apoptosis evasion, the apoptosis-pyroptosis transition, ER stress adaptation, extracellular matrix remodeling, and metastasis. Matrix metalloproteinase-2 (MMP-2) was described as a key mediator of extracellular matrix remodeling and cancer metastasis. Other studies examined cuproptosis-mediated cancer therapy, STING agonists, TLR7/8 modulators, and CRISPR-based epigenetic editing, all of which reflect attempts to manipulate signaling and regulatory networks that support malignant progression. Mitochondrial dysfunction and mitochondria-organelle collaboration were also discussed as disease-relevant processes, with cancer included among the major pathological conditions linked to these mechanisms.
Nanotechnology and targeted delivery were recurring themes. Publications described bioresponsive nanomedicines, metal-organic framework-based drug delivery systems, lipid nanoparticles, nanobody-based Targeted Cancer Therapy, and polysaccharide/lipid composite nanovesicles for precision cancer therapy. These platforms were presented as ways to improve tumor accumulation, reduce systemic off-target effects, and enhance delivery of drugs, genes, proteins, or photosensitizers. Sonodynamic therapy and gas therapy were also reviewed as combinatorial strategies for malignant tumors, illustrating the continued search for multimodal treatment approaches.
Diagnostic and prognostic research was equally active. Early-stage oncology diagnosis was emphasized as critical for improving survival, quality of life, and health system efficiency. AI-driven imaging, precision oncology, tumor-only variant calling, mutation burden estimation, and multi-omics biomarker studies were all used to improve detection, stratification, and treatment planning. One study on baseline D-dimer as a predictor of immune checkpoint inhibitor efficacy underscored the ongoing effort to identify biomarkers that can forecast response to therapy. Another publication on global burden of cancer in children and adolescents highlighted the importance of epidemiologic data for cancer policy planning.
The literature also reflects the broad clinical and psychosocial impact of malignant disease. Studies on cancer care coordination, patient perceptions of care team selection, mobile sensor data integration, and the bidirectional relationship between cancer and depression show that malignant disease affects not only tumor biology but also care delivery, mental health, and health-system organization. In addition, work on cadmium-related lung toxicity and carcinogenesis, CKM syndrome severity as a risk factor for cancer, and childhood cancer burden demonstrates that malignant disease is studied in relation to environmental exposures, metabolic risk, and population-level outcomes.